|
1
|
Webb PM and Jordan SJ: Epidemiology of
epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol.
41:3–14. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Reid BM, Permuth JB and Sellers TA:
Epidemiology of ovarian cancer: A review. Cancer Biol Med. 14:9–32.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pierredon S, Ribaux P, Tille JC, Petignat
P and Cohen M: Comparative secretome of ovarian serous carcinoma:
Gelsolin in the spotlight. Oncol Lett. 13:4965–4973. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Howlader N, Noone A, Krapcho M, Neyman N,
Aminou R, Waldron W, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z,
et al: SEER Cancer Statistics Review, 1975–2008, National Cancer
Institute.
|
|
5
|
Grunewald T and Ledermann JA: Targeted
Therapies for Ovarian Cancer. Best Pract Res Clin Obstet Gynaecol.
41:139–152. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kim JY, Cho CH and Song HS: Targeted
therapy of ovarian cancer including immune check point inhibitor.
Korean J Intern Med. 32:798–804. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Brasseur K, Gévry N and Asselin E:
Chemoresistance and targeted therapies in ovarian and endometrial
cancers. Oncotarget. 8:4008–4042. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lintner NG and Cate J: Regulating the
ribosome: A spotlight on RNA dark matter. Mol Cell. 54:1–2. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ponting CP, Oliver PL and Rei W: Evolution
and functions of long noncoding RNAs. Cell. 136:629–641. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cesana M, Cacchiarelli D, Legnini I,
Santini T, Sthandier O, Chinappi M, Tramontano A and Bozzoni I: A
long noncoding RNA controls muscle differentiation by functioning
as a competing endogenous RNA. Cell. 147:358–369. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kitagawa M, Kitagawa K, Kotake Y, Niida H
and Ohhata T: Cell cycle regulation by long non-coding RNAs. Cell
Mol Life Sci. 70:4785–4794. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang XM, Yang GL, Le XH, et al:
Expression profiles of long non-coding RNA in HCC patients
suffering hepatitis B liver cirrhosis. J Zhengzhou Univ (Med Sci).
50:194–198. 2015.
|
|
13
|
Yu T, Zhao Y, Hu Z, Li J, Chu D, Zhang J,
Li Z, Chen B, Zhang X, Pan H, et al: MetaLnc9 facilitates lung
cancer metastasis via a PGK1-activated AKT/mTOR pathway. Cancer
Res. 77:5782–5794. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Su W, Xu M, Chen X, Chen N, Gong J, Nie L,
Li L, Li X, Zhang M and Zhou Q: Long noncoding RNA ZEB1-AS1
epigenetically regulates the expressions of ZEB1 and downstream
molecules in prostate cancer. Mol Cancer. 16:1422017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Dey BK, Mueller AC and Dutta A: Long
non-coding RNAs as emerging regulators of differentiation,
development, and disease. Transcription. 5:e9440142014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Iguchi T, Uchi R, Nambara S, Saito T,
Komatsu H, Hirata H, Ueda M, Sakimura S, Takano Y, Kurashige J, et
al: A long noncoding RNA, lncRNA-ATB, is involved in the
progression and prognosis of colorectal cancer. Anticancer Res.
35:1385–1388. 2015.PubMed/NCBI
|
|
17
|
Fu N, Zhao SX, Kong LB, Du JH, Ren WG, Han
F, Zhang QS, Li WC, Cui P, Wang RQ, et al:
LncRNA-ATB/microRNA-200a/β-catenin regulatory axis involved in the
progression of HCV-related hepatic fibrosis. Gene. 618:1–7. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ke L, Xu SB, Wang J, Jiang XL and Xu MQ:
High expression of long non-coding RNA ATB indicates a poor
prognosis and regulates cell proliferation and metastasis in
non-small cell lung cancer. Clin Transl Oncol. 19:599–605. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chen S, Zhang L, Yan G, Cheng S, Fathy AH,
Yan N and Zhao Y: Neutrophil-to-lymphocyte ratio is a potential
prognostic biomarker in patients with ovarian cancer: A
Meta-analysis. Biomed Res Int. 2017:79434672014.
|
|
21
|
Wang J, Zhao Y, Qi R, Zhu X, Huang C,
Cheng S, Wang S and Qi X: Prognostic role of podocalyxin-like
protein expression in various cancers: A systematic review and
meta-analysis. Oncotarget. 8:52457–52464. 2017.PubMed/NCBI
|
|
22
|
Zhou Y, Cheng S, Chen S and Zhao Y:
Prognostic and clinicopathological value of SIRT3 expression in
various cancers: A systematic review and meta-analysis. OncoTargets
Ther. 11:2157–2167. 2018. View Article : Google Scholar
|
|
23
|
Zhou Y, Cheng S, Fathy AH, Qian H and Zhao
Y: Prognostic value of platelet-tolymphocyte ratio in pancreatic
cancer: A comprehensive meta-analysis of 17 cohort studies.
OncoTargets Ther. 11:1899–1908. 2018. View Article : Google Scholar
|
|
24
|
Zhao Y, Si G, Zhu F, Hui J, Cai S, Huang
C, Cheng S, Fathy AH, Xiang Y and Li J: Prognostic role of platelet
to lymphocyte ratio in hepatocellular carcinoma: A systematic
review and meta-analysis. Oncotarget. 8:22854–22862. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Song X, Yao H, Liu J and Wang Q: The
prognostic value of long noncoding RNA Sox2ot expression in various
cancers: A systematic review and meta-analysis. Clin Chim Acta.
484:52–59. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hu Y, Chen HY, Yu CY, Xu J, Wang JL, Qian
J, Zhang X and Fang JY: A long non-coding RNA signature to improve
prognosis prediction of colorectal cancer. Oncotarget. 5:2230–2242.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Beckedorff FC, Amaral MS,
Deocesano-Pereira C and Verjovski-Almeida S: Long non-coding RNAs
and their implications in cancer epigenetics. Biosci Rep. 33(pii):
e000612013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gutschner T and Diederichs S: The
hallmarks of cancer: A long non-coding RNA point of view. RNA Biol.
9:703–719. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chen Y, Wei G, Xia H, Tang Q and Bi F:
Long noncoding RNAATB promotes cell proliferation, migration and
invasion in gastric cancer. Mol Med Rep. 17:1940–1946.
2018.PubMed/NCBI
|
|
30
|
Fu XM, Guo W, Li N, Liu HZ, Liu J, Qiu SQ,
Zhang Q, Wang LC, Li F and Li CL: The expression and function of
long noncoding RNA lncRNA-ATB in papillary thyroid cancer. Eur Rev
Med Pharmacol Sci. 21:3239–3246. 2017.PubMed/NCBI
|
|
31
|
Karlsson MC, Gonzalez SF, Welin J and Fuxe
J: Epithelial-mesenchymal transition in cancer metastasis through
the lymphatic system. Mol Oncol. 11:781–791. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Liao TT and Yang MH: Revisiting
epithelial-mesenchymal transition in cancer metastasis: The
connection between epithelial plasticity and stemness. Mol Oncol.
11:792–804. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Davis FM, Azimi I, Faville RA, Peters AA,
Jalink K, Putney JW Jr, Goodhill GJ, Thompson EW, Roberts-Thomson
SJ, Monteith GR, et al: Induction of epithelial-mesenchymal
transition (EMT) in breast cancer cells is calcium signal
dependent. Oncogene. 33:2307–2316. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yoshida T, Ozawa Y, Kimura T, Sato Y,
Kuznetsov G, Xu S, Uesugi M, Agoulnik S, Taylor N, Funahashi Y and
Matsui J: Eribulin mesilate suppresses experimental metastasis of
breast cancer cells by reversing phenotype from
epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial
transition (MET) states. Br J Cancer. 110:1497–1505. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Qu C, Zhang W, Zheng G, Zhang Z, Yin J and
He Z: Metformin reverses multidrug resistance and
epithelial-mesenchymal transition (EMT) via activating
AMP-activated protein kinase (AMPK) in human breast cancer cells.
Mol Cell Biochem. 386:63–71. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Vetuschi A, Pompili S, Flati V, Berardinis
LD, Di Gregorio J, Latella G and Sferra R:
Epithelial-to-Mesenchimal Transition (EMT) in experimental
intestinal fibrosis. Italian J Anatomy Embryology. 120:582015.
|
|
37
|
Yang Y, Gao M, Lin Z, Chen L, Jin Y, Zhu
G, Wang Y and Jin T: DEK promoted EMT and angiogenesis through
regulating PI3K/AKT/mTOR pathway in triple-negative breast cancer.
Oncotarget. 8:98708–98722. 2017.PubMed/NCBI
|
|
38
|
Ma Z, Xin Z, Hu W, Jiang S, Yang Z, Yan X,
Li X, Yang Y and Chen F: Forkhead box O proteins: Crucial
regulators of cancer EMT. Semin Cancer Biol. 50:21–31. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zuo L, Zhao H, Yang R, Wang L, Ma H, Xu X,
Zhou P and Kong L: Lamin A/C might be involved in the EMT
signalling pathway. Gene. 663:51–64. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhao J, Du P, Cui P, Qin Y, Hu C, Wu J,
Zhou Z, Zhang W, Qin L and Huang G: LncRNA PVT1 promotes
angiogenesis via activating the STAT3/VEGFA axis in gastric cancer.
Oncogene. 37:4094–4109. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Egusquiaguirre SP, Yeh JE, Walker SR, Liu
S and Frank DA: The STAT3 Target Gene TNFRSF1A Modulates the NF-κB
Pathway in Breast Cancer Cells. Neoplasia. 20:489–498. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Bournazou E and Bromberg J: Targeting the
tumor microenvironment: JAK-STAT3 signaling. JAKSTAT.
2:e238282013.PubMed/NCBI
|
|
43
|
Chen L, Wang J, Wu J, Zheng Q and Hu J:
Indirubin suppresses ovarian cancer cell viabilities through the
STAT3 signaling pathway. Drug Des Devel Ther. 12:3335–3342. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Jia ZH, Jia Y, Guo FJ, Chen J, Zhang XW
and Cui MH: Phosphorylation of STAT3 at Tyr705 regulates MMP-9
production in epithelial ovarian cancer. PLoS One. 12:e01836222017.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Saini U, Naidu S, ElNaggar AC, Bid HK,
Wallbillich JJ, Bixel K, Bolyard C, Suarez AA, Kaur B, Kuppusamy P,
et al: Elevated STAT3 expression in ovarian cancer ascites promotes
invasion and metastasis: A potential therapeutic target. Oncogene.
36:168–181. 2017. View Article : Google Scholar : PubMed/NCBI
|
